Novo Nordisk's Unsolicited Bid for Metsera Inc. Sparks Competition with Pfizer

Novo Nordisk A/S has made a significant unsolicited bid for the U.S. biotech firm Metsera Inc., valued at up to $9 billion, which has ignited a competitive clash with Pfizer Inc. This move comes as both companies vie for dominance in the lucrative obesity treatment market, projected to reach $150 billion by the early 2030s. Novo's offer includes $6 billion upfront and potential milestone payments of $2.5 billion, surpassing Pfizer's earlier agreement with Metsera, which was worth approximately $7.3 billion.

Novo Nordisk locks horns with Pfizer in late bid for MetseraReutersFierce BiotechThe GuardianBioSpace

Novo Nordisk's proposal values Metsera at $77.75 per share, which is 11% higher than Pfizer's maximum bid of $70 per share. Metsera has indicated that Novo's offer is "superior" and has given Pfizer four business days to negotiate a revised proposal. If Metsera decides to accept Novo's bid, it could terminate its agreement with Pfizer. The structure of Novo's bid allows for significant upfront payments, which is atypical in such acquisitions, potentially circumventing some regulatory hurdles.

CityLabNovo Nordisk locks horns with Pfizer in late bid for MetseraBioSpaceReuters

Pfizer has responded critically to Novo's bid, labeling it "reckless" and an attempt to suppress competition. The company argues that Novo's dominant market position raises substantial antitrust concerns and has pledged to pursue all legal avenues to protect its interests. Pfizer's CEO Albert Bourla emphasized that the bid could violate laws aimed at maintaining fair competition in the pharmaceutical industry.

The Guardian

The bidding war reflects a broader trend in the pharmaceutical industry, where major companies are aggressively pursuing smaller biotech firms to enhance their portfolios, particularly in the obesity treatment sector. Novo's recent strategic shifts, including significant job cuts and leadership changes under new CEO Maziar Mike Doustdar, underscore its commitment to reclaiming market share lost to competitors like Eli Lilly & Co., which currently holds a substantial portion of the obesity drug market.

CityLab

Critics of Novo's bid have raised concerns about the potential regulatory risks associated with the acquisition, particularly given Novo's existing position in the obesity market. Analysts have noted that while the bid could strengthen Novo's competitive stance, it also carries the risk of prolonged regulatory scrutiny, which could delay the acquisition process.

Reuters

• “By GlobalData Learn more about Strategic Intelligence In a statement, Pfizer said: “It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger.” — Pfizer

Novo Nordisk locks horns with Pfizer in late bid for Metsera

• “Novo Nordisk is flexing its muscles,” — Per Hansen, Investment Economist at Nordnet AB

CityLab

• “The proposal is illusory and cannot qualify as a superior proposal under Pfizer’s agreement with Metsera,” — Pfizer

BioSpace

The outcome of this bidding war will depend on Pfizer's response within the stipulated negotiation period. If Pfizer fails to present a more attractive offer, Metsera may proceed with Novo's bid, marking a significant shift in the competitive landscape of the obesity treatment market. The situation remains dynamic, with potential implications for both companies' future strategies and market positions.

Novo Nordisk locks horns with Pfizer in late bid for Metsera